ProCE Banner Activity

Driving Improved Outcomes in Resectable Melanoma: Pathways for Optimized Adjuvant Immunotherapy Strategies


Download this slideset to learn the latest on incorporating adjuvant immunotherapy into the management of early-stage melanoma.

Released: November 30, 2023



Michael A. Davies

Michael A. Davies, MD, PhD

Professor and Chair, Department of Melanoma Medical Oncology
Professor, Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair in Cancer Research
University of Texas, MD Anderson Cancer Center
Houston, Texas

April Salama

April Salama, MD

Associate Professor of Medicine
Division of Medical Oncology
Director, Melanoma Program
Duke Cancer Institute
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC, in partnership with AIM at Melanoma Foundation.

ProCE Banner


Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb


AIM at Melanoma Foundation

ProCE Banner